Circulating cytotoxic anti-RCC antibody responses in renal cell carcinoma patients.
The circulating anti-RCC cytotoxic antibodies of eighteen RCC patients, preoperatively, and one inoperable case were studied by 51Cr release CDC and ADCC assays, using the cultured human RCC cell line, OUR-10. Circulating cytotoxic anti-RCC antibodies were detected in eight patients as CDC antibodies. The patients with a low pathological grade had a significantly higher percentage (P less than 0.05) of positive antibody responses.